Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IntegraGen S.A. (ALINT.PA)
Évry, FR
IntegraGen S.A. provides advanced human genome analysis services to academic researchers and life science businesses across France. Their comprehensive genomic offerings include transcriptomics, epigenomics, DNA sequencing, next-generation sequencing (NGS) specifically for cancer research, and SNP genotyping. The company also delivers clinical research solutions, such as clinical-grade sequencing and pharmacogenomic studies, in addition to supporting fundamental human genetic investigations. For agricultural applications, IntegraGen offers agrigenomic services covering crop and livestock genotyping, as well as high-throughput sequencing for these domains. Their microbial genomics division conducts whole-genome microbial sequencing and transcriptomics. IntegraGen further develops a suite of sophisticated bioinformatics tools: MERCURY is an online platform for oncology, designed to transform raw high-throughput sequencing data into molecular reports for translational and clinical research. SIRIUS, a cloud-based software, empowers researchers to analyze whole genome, whole exome, and gene panel sequencing information. Galileo is another cloud application that enables dynamic exploration of RNA-Seq expression data. Finally, GeCo, their genomic consulting service, provides researchers access to expert biostatisticians and bioanalysts. Founded in 2000 and headquartered in Évry, France, IntegraGen S.A. is a subsidiary of OncoDNA SA.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.26% | -8.86% | +6.51% | +1.41% | +16.50% | +35.34% | -69.70% | -85.71% | -90.48% | -94.64% | -98.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-42.3% Q4'25: -62.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-952.6% Q4'25: -1,404.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-39.4% Q4'25: -37.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-56.2% Q4'25: -53.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +293.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q4'25: +4.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.11× Q4'25: -0.06× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.79M
est: 9.40M (-38.4%)
|
6.27M
est: 6.02B (-99.9%)
|
6.51M
est: 6.50M (+0.1%)
|
6.95M
est: 6.02B (-99.9%)
|
8.28M
est: 6.50M (+27.4%)
|
8.98M
est: 7.30M (+23.0%)
|
11.32M
est: 10.50M (+7.8%)
|
13.17M
est: 12.30M (+7.0%)
|
12.54M
est: 12.20M (+2.8%)
|
8.70M
est: 12.20M (-28.7%)
|
5.02M
est: 6.50M (-22.8%)
|
6.50M
6.50M – 6.50M
+0.0% YoY
|
7.30M
7.30M – 7.30M
+12.3% YoY
|
10.50M
10.50M – 10.50M
+43.8% YoY
|
12.30M
12.30M – 12.30M
+17.1% YoY
|
12.20M
12.20M – 12.20M
-0.8% YoY
|
| EBITDA |
-1.45M
est: -95.2K (-1,417.6%)
|
-1.67M
est: -61.01M (+97.3%)
|
-1.81M
est: -2.15M (+16.1%)
|
-1.20M
est: -61.01M (+98.0%)
|
-179.2K
est: -1.45M (+87.6%)
|
-235.9K
est: -74.0K (-219.0%)
|
96.5K
est: -106.4K (+190.7%)
|
70.0K
est: -124.6K (+156.1%)
|
-52.5K
est: -123.6K (+57.5%)
|
-296.0K
est: -1.41M (+79.0%)
|
-2.78M
est: -750.9K (-269.9%)
|
-750.9K
-750.9K – -750.9K
+0.0% YoY
|
-843.3K
-843.3K – -843.3K
-12.3% YoY
|
-1.21M
-1.21M – -1.21M
-43.8% YoY
|
-1.42M
-1.42M – -1.42M
-17.1% YoY
|
-1.41M
-1.41M – -1.41M
+0.8% YoY
|
| EBIT |
-1.86M
est: -247.6K (-651.2%)
|
-1.92M
est: -158.64M (+98.8%)
|
-1.20M
est: -2.27M (+47.3%)
|
-1.33M
est: -158.64M (+99.2%)
|
-435.3K
est: -1.44M (+69.7%)
|
-462.2K
est: -192.3K (-140.4%)
|
-109.4K
est: -276.6K (+60.4%)
|
-131.6K
est: -324.0K (+59.4%)
|
-250.7K
est: -321.4K (+22.0%)
|
-353.0K
est: -1.57M (+77.5%)
|
-2.82M
est: -835.1K (-238.0%)
|
-835.1K
-835.1K – -835.1K
+0.0% YoY
|
-937.9K
-937.9K – -937.9K
-12.3% YoY
|
-1.35M
-1.35M – -1.35M
-43.8% YoY
|
-1.58M
-1.58M – -1.58M
-17.1% YoY
|
-1.57M
-1.57M – -1.57M
+0.8% YoY
|
| Net Income |
-1.53M
est: -1.89M (+18.7%)
|
-1.65M
est: -404.2K (-308.4%)
|
-862.2K
est: -1.91M (+54.9%)
|
-1.14M
est: -404.2K (-182.0%)
|
-285.0K
est: -1.24M (+77.1%)
|
-375.0K
est: -1.61M (+76.7%)
|
15.4K
est: -429.5K (+103.6%)
|
-3.5K
est: -63.0K (+94.4%)
|
-171.4K
est: 336.2K (-151.0%)
|
-256.0K
est: 335.7K (-176.3%)
|
-2.66M
est: -1.48M (-80.6%)
|
-1.48M
-1.48M – -1.48M
+0.0% YoY
|
-1.60M
-1.60M – -1.60M
-8.8% YoY
|
-428.9K
-428.9K – -428.9K
+73.3% YoY
|
-62.9K
-62.9K – -62.9K
+85.3% YoY
|
335.7K
335.7K – 335.7K
+633.9% YoY
|
| SGA |
3.22M
est: 1.45M (+122.4%)
|
2.99M
est: 926.67M (-99.7%)
|
2.95M
est: 3.58M (-17.5%)
|
3.17M
est: 926.67M (-99.7%)
|
5.83M
est: 3.56M (+63.6%)
|
216.6K
est: 1.12M (-80.7%)
|
171.1K
est: 1.62M (-89.4%)
|
335.2K
est: 1.89M (-82.3%)
|
4.61M
est: 1.88M (+145.6%)
|
2.93M
est: 5.76M (-49.1%)
|
8.12M
est: 3.07M (+164.4%)
|
3.07M
3.07M – 3.07M
+0.0% YoY
|
3.45M
3.45M – 3.45M
+12.3% YoY
|
4.96M
4.96M – 4.96M
+43.8% YoY
|
5.81M
5.81M – 5.81M
+17.1% YoY
|
5.76M
5.76M – 5.76M
-0.8% YoY
|
| EPS |
-0.31
est: -0.28 (-10.7%)
|
-0.33
est: -0.06 (-450.0%)
|
-0.13
est: -0.22 (+40.7%)
|
-0.18
est: -0.06 (-200.0%)
|
-0.04
est: -0.22 (+80.0%)
|
-0.06
est: -0.24 (+76.4%)
|
0.00
est: -0.06 (+103.6%)
|
0.00
est: -0.01 (+94.7%)
|
-0.03
est: 0.05 (-151.9%)
|
-0.04
est: 0.05 (-176.2%)
|
-0.40
est: -0.22 (-82.4%)
|
-0.22
-0.22 – -0.22
+0.0% YoY
|
-0.24
-0.24 – -0.24
-8.8% YoY
|
-0.06
-0.06 – -0.06
+73.3% YoY
|
-0.01
-0.01 – -0.01
+85.3% YoY
|
0.05
0.05 – 0.05
+633.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anne Philippi | Co-Founder and Director of Bio-Statistics & Genetic Epidemiology | — | female |
| Beatrice Cosperec | Legal Manager | — | female |
| Berengere Genin | General Manager | — | female |
| Celine Capera | Sales Manager | — | female |
| Manuelle Puisant | Director of Human Resources | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALINT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
